Open AccessPrognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13660
Subject(s) - medicine , oncology , cancer , biomarker , endocrine system , clinical trial , breast cancer , hormone , biochemistry , chemistry
According to a new biomarker analysis of the MONALEESA trials, intrinsic tumor subtype is an important predictor of clinical outcomes in patients with HR‐positive/HER2‐negative breast cancer treated with ribociclib and endocrine therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom